CN112930341A - 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐 - Google Patents
无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐 Download PDFInfo
- Publication number
- CN112930341A CN112930341A CN201980071335.3A CN201980071335A CN112930341A CN 112930341 A CN112930341 A CN 112930341A CN 201980071335 A CN201980071335 A CN 201980071335A CN 112930341 A CN112930341 A CN 112930341A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- amorphous
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201800783 | 2018-10-29 | ||
DKPA201800783 | 2018-10-29 | ||
PCT/EP2019/079350 WO2020089147A1 (en) | 2018-10-29 | 2019-10-28 | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112930341A true CN112930341A (zh) | 2021-06-08 |
Family
ID=68392992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980071335.3A Pending CN112930341A (zh) | 2018-10-29 | 2019-10-28 | 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210395208A1 (zh) |
EP (1) | EP3873885A1 (zh) |
JP (1) | JP7442538B2 (zh) |
CN (1) | CN112930341A (zh) |
WO (1) | WO2020089147A1 (zh) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
BRPI0413595B8 (pt) | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
CN102065861B (zh) | 2008-05-07 | 2013-10-16 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪用于改善认知的用途 |
EP2344163A1 (en) | 2008-10-03 | 2011-07-20 | H. Lundbeck A/S | Oral formulation |
PL2720989T3 (pl) * | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
AR094054A1 (es) | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
-
2019
- 2019-10-28 EP EP19795536.2A patent/EP3873885A1/en active Pending
- 2019-10-28 JP JP2021547917A patent/JP7442538B2/ja active Active
- 2019-10-28 US US17/289,518 patent/US20210395208A1/en active Pending
- 2019-10-28 WO PCT/EP2019/079350 patent/WO2020089147A1/en unknown
- 2019-10-28 CN CN201980071335.3A patent/CN112930341A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3873885A1 (en) | 2021-09-08 |
WO2020089147A1 (en) | 2020-05-07 |
JP2022509408A (ja) | 2022-01-20 |
JP7442538B2 (ja) | 2024-03-04 |
US20210395208A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI404719B (zh) | 組合物及其用途 | |
TWI788702B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 | |
US8227463B2 (en) | Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | |
CN112353762A (zh) | 具有改善的生物利用度的药物组合物 | |
JP2010539237A (ja) | N−(5−tert−ブチル−イソオキサゾール−3−イル)−N’−{4−[7−(2−モルホリン−4−イル−エトキシ)イミダゾ[2,1−b][1,3]ベンゾチアゾール−2−イル]フェニル}ウレアを含む固形、その組成物、及びその用途 | |
EP3143004B1 (en) | Amorphous form of apremilast | |
US20140341993A1 (en) | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof | |
US20180193334A1 (en) | Pharmaceutical composition of vortioxetine or salt thereof, and preparation method therefor | |
WO2015176591A1 (zh) | 贝曲西班盐及其制备方法和用途 | |
US20230203009A1 (en) | Pralsetinib pharmaceutical compositions | |
WO2011101862A1 (en) | Stabilized fluconazole polymorph iii formulation | |
RU2598378C2 (ru) | Кристаллические формы iii и iv n-бензоилстауроспорина | |
US20210323944A1 (en) | Ivosidenib forms and pharmaceutical compositions | |
JP7442538B2 (ja) | 非晶性の式(i)の化合物及び非晶性の式(i)の化合物塩 | |
JP2019509306A (ja) | Jak関連疾患の治療又は予防に用いる薬物の塩酸塩の結晶形及びその製造方法 | |
CN113490492A (zh) | 吡唑酰胺化合物的非晶质固体分散体 | |
KR101423630B1 (ko) | 비칼루타미드와 니코틴아미드의 공결정 | |
WO2022253261A1 (zh) | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 | |
EP2832723B1 (en) | Stabilised amorphous forms of Saxagliptin | |
WO2022013153A1 (en) | Polymorphs of a hydrochloride salt of pn6047 | |
CA3235361A1 (en) | Polymorphs of the hydrochloride salt of linaprazan glurate | |
CZ2017207A3 (cs) | Amorfní pevná forma suvorexantu stabilizovaná aminokyselinami |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40053332 Country of ref document: HK |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210608 Assignee: NHWA PHARMA. Corp. Assignor: H.Lundbeck gmbh Contract record no.: X2022990000498 Denomination of invention: Amorphous compounds of formula (I) and amorphous salts of compounds of formula (I) License type: Exclusive License Record date: 20220811 |